These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8585000)

  • 1. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
    Lynch JJ; Sitko GR; Lehman ED; Vlasuk GP
    Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
    Rebello SS; Blank HS; Rote WE; Vlasuk GP; Lucchesi BR
    J Pharmacol Exp Ther; 1997 Oct; 283(1):91-9. PubMed ID: 9336312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
    Vlasuk GP; Ramjit D; Fujita T; Dunwiddie CT; Nutt EM; Smith DE; Shebuski RJ
    Thromb Haemost; 1991 Mar; 65(3):257-62. PubMed ID: 2048051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ; Cook JJ; Sitko GR; Holahan MA; Ramjit DR; Mellott MJ; Stranieri MT; Stabilito II; Zhang G; Lynch RJ
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S; Tschopp T; Baumgartner HR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
    Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs.
    Abendschein DR; Recchia D; Meng YY; Oltrona L; Wickline SA; Eisenberg PR
    J Am Coll Cardiol; 1996 Dec; 28(7):1849-55. PubMed ID: 8962575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
    Lefkovits J; Malycky JL; Rao JS; Hart CE; Plow EF; Topol EJ; Nicolini FA
    J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
    J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
    Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
    Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
    Schaffer LW; Davidson JT; Vlasuk GP; Siegl PK
    Circulation; 1991 Oct; 84(4):1741-8. PubMed ID: 1833089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
    Wong PC; Crain EJ; Knabb RM; Meade RP; Quan ML; Watson CA; Wexler RR; Wright MR; Slee AM
    J Pharmacol Exp Ther; 2000 Oct; 295(1):212-8. PubMed ID: 10991981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis.
    Romson JL; Hook BG; Lucchesi BR
    J Pharmacol Exp Ther; 1983 Nov; 227(2):288-94. PubMed ID: 6313894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.